Monte Rosa Therapeutics, Inc.
GLUE
$4.59
-$0.23-4.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.30M | 46.89M | 13.44M | -23.86M | -30.31M |
| Total Depreciation and Amortization | 2.72M | 2.65M | 2.56M | 2.70M | 2.27M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.57M | 3.61M | 3.27M | 2.59M | 3.20M |
| Change in Net Operating Assets | -28.71M | -98.64M | 109.65M | -2.43M | -2.93M |
| Cash from Operations | -34.72M | -45.49M | 128.92M | -20.99M | -27.77M |
| Capital Expenditure | -1.70M | -1.59M | -183.00K | -399.00K | -2.02M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 27.02M | -98.64M | -30.71M | 38.15M | -59.14M |
| Cash from Investing | 25.32M | -100.23M | -30.90M | 37.75M | -61.16M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 365.00K | 14.00K | 3.61M | 15.00K | 51.66M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -3.00M | 0.00 | 46.36M |
| Cash from Financing | 365.00K | 14.00K | 608.00K | 15.00K | 98.02M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.03M | -145.71M | 98.63M | 16.77M | 9.10M |